Immunocyt Test Improves the Diagnostic Accuracy of Urinary Cytology: Results of a French Multicenter Study

• DOI: 10.1097/01.ju.0000048983.83079.4c
• Publication Date: 2003-11-18T22:40:09Z
• Authors: CHRISTIAN PFISTER; DENIS CHAUTARD; MARIAN DEVONEC; PAUL PERRIN; DOMINIQUE CHOPIN; PASCAL RISCHMANN; OLIVIER BOUCHOT; DANIEL BEURTON; CHRISTIAN COULANGE; JEAN-JACQUES RAMB...
• Keywords: Urine cytology; Gold standard (test); Histopathology

No AccessJournal of UrologyCLINICAL UROLOGY: Original Articles1 Mar 2003Immunocyt Test Improves the Diagnostic Accuracy Urinary Cytology: Results a French Multicenter Study CHRISTIAN PFISTER, DENIS CHAUTARD, MARIAN DEVONEC, PAUL PERRIN, DOMINIQUE CHOPIN, PASCAL RISCHMANN, OLIVIER BOUCHOT, DANIEL BEURTON, COULANGE, and JEAN-JACQUES RAMBEAUD PFISTERCHRISTIAN PFISTER , CHAUTARDDENIS CHAUTARD DEVONECMARIAN DEVONEC PERRINPAUL PERRIN CHOPINDOMINIQUE CHOPIN RISCHMANNPASCAL RISCHMANN BOUCHOTOLIVIER BOUCHOT BEURTONDANIEL BEURTON COULANGECHRISTIAN COULANGE RAMBEAUDJEAN-JACQUES View All Author Informationhttps://doi.org/10.1097/01.ju.0000048983.83079.4cAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: The limitations urinary cytology invasiveness cystoscopy generate an increasing interest in noninvasive diagnostic tools for management transitional cell carcinoma. We assess clinical performance ImmunoCyt (DiagnoCure, Inc., Saint-Foy, Canada) detection bladder cancer 10-center trial. Materials Methods: From October 2000 April 2001, 694 patients undergoing were prospectively included study. Of 458 (66%) had been previously treated superficial carcinoma 236 (34%) referred symptoms suggestive cancer. underwent test standard from voided urine as well complete evaluation including transurethral resection or biopsy suspicious lesions. Sensitivity specificity values whether not combined calculated using gold histopathology when available. Results: A total 85 recurrent 58 newly diagnosed tumors by histologicaly confirmed. Overall sensitivity was 17.9%, 46.3% 63.8% respectively, G1, G2 G3 carcinoma, whereas that 60.7%, 75.6% 76.8%. tests 66.7%, 78% 87%, respectively. Moreover, 10 55 (18.2%) new pT1 pT2 greater alone. Specificity 94.5%, 84.2%. 80.7%. Marked variations observed among different centers (27.3% 66.7%), assays (urinary ImmunoCyt) enhanced overall 80% range at most centers. Conclusions: This prospective multicenter series confirmed marked increase without significant loss protocol. increased high grade lesions (with 100% situ) low grade, stage tumors. References 1 : Prognostic factors recurrence followup policies treatment cancer: report British Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Working Party). J Urol1989; 142: 284. Link, Google Scholar 2 Factors affecting progression tumours. Eur Cancer1995; 31A: 1840. 3 Current tumor tests: does their projected utility fulfill necessity?. Urol2001; 165: 1067. 4 Noninvasive with BTA stat test. Urol1999; 161: 443. 5 NMP22 after bladder: experience 137 patients. Urology1998; 52: 793. Crossref, Medline, 6 Initial UBC marker 1110. 7 Curr Opin Oncol2000; 12: 255. 8 Performance characteristics monoclonal antibody Immunocyt Canad Urol1997; 4: 400. 9 Immunocyt: tool detecting tract. 1486. World Health Organization/International Society Urological Pathology consensus classification urothelial (transitional cell) neoplasms bladder. Consensus Conference Committee. Am Surg Pathol1998; 22: 1435. 11 accuracy cytology, deoxyribonucleic acid flow cytometry washings during 157: 1660. 12 early diagnosis critical review options. 39: 619. 13 Comparison molecular conventional strategies decision analysis. Urol2000; 163: 752. 14 Can bound replace cancer?. Urol1998; 159: 1876. 15 Transurethral surveillance supported 5-aminolevulinic acid-induced fluorescence endoscopy. 36: 386. 16 ImmunoCytTM: useful method follow-up protocol Scand Urol Nephrol2001; 35: 280. 17 efficacy detect recurrence. Urology2001; 58: 367. 18 infection following out-patient flexible cystoscopy. Br Urol1990; 66: 503. 19 natural history risk 15-year outcome. 158: 62. 20 Detection upper tract ImmunoCyt: preliminary report. 362. Urology Department, Charles Nicolle University Hospital, Rouen, Angers, Pierre Benite Hospital Antiquaille Lyon, Henri Mondor Creteil, Purpan Toulouse, Hôtel Dieu Nantes, Ambroise Pare Boulogne Billancourt, Salvatore Marseille, Grenoble, France© 2003 American Association, Inc.FiguresReferencesRelatedDetailsCited byO'Sullivan P, Sharples K, Dalphin M, Davidson Gilling Cambridge L, Harvey J, Toro T, Giles N, Luxmanan C, Alves Yoon H, Hinder V, Masters Kennedy-Smith A, Beaven T Guilford P (2012) Multigene Urine Stratification Patients Presenting HematuriaJournal Urology, VOL. 188, NO. 3, (741-747), Online publication date: 1-Sep-2012.Lotan Y, Bensalah Ruddell Shariat S, Sagalowsky Ashfaq R (2008) Prospective Evaluation Clinical Usefulness Reflex Fluorescence In Situ Hybridization Assay With Atypical Cytology Urothelial Carcinoma BladderJournal 179, 6, (2164-2169), 1-Jun-2008.Bartoletti R, Cai Dal Canto Boddi Nesi G Piazzini M (2018) Multiplex Polymerase Chain Reaction Microsatellite Analysis Sediment Cells: Rapid Inexpensive Method Diagnosing Monitoring Transitional Cell CarcinomaJournal 175, (2032-2037), 1-Jun-2006.MESSING E, TEOT KORMAN UNDERHILL BARKER STORK B, QIAN BOSTWICK D PERFORMANCE OF URINE TEST IN PATIENTS MONITORED FOR RECURRENCE BLADDER CANCER: MULTICENTER STUDY THE UNITED STATESJournal 174, Part 1, (1238-1241), 1-Oct-2005. Volume 169Issue 3March 2003Page: 921-924 Advertisement Copyright & Permissions© Inc.Keywordsantibodies, monoclonalfluorescencebladder neoplasmscystoscopyMetricsAuthor Information Requests reprints: Department Urology; Rouen Rue de Germont, 76031 France. More articles this author Expand PDF downloadLoading ...